No announcement yet.

mBio. Prion Disease Blood Test Using Immunoprecipitation and Improved Quaking-Induced Conversion

  • Filter
  • Time
  • Show
Clear All
new posts

  • mBio. Prion Disease Blood Test Using Immunoprecipitation and Improved Quaking-Induced Conversion

    [Source: mBio, full text: (LINK). Abstract, edited.]
    Prion Disease Blood Test Using Immunoprecipitation and Improved Quaking-Induced Conversion

    1. Christina D. Orrú<SUP>a</SUP>,
    2. Jason M. Wilham<SUP>a</SUP>,
    3. Lynne D. Raymond<SUP>a</SUP>,
    4. Franziska Kuhn<SUP>b</SUP>,
    5. Björn Schroeder<SUP>b</SUP>,
    6. Alex J. Raeber<SUP>b</SUP>, and
    7. Byron Caughey<SUP>a</SUP>

    Author Affiliations
    Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA,<SUP>a</SUP> and Prionics AG, Zurich, Switzerland<SUP>b </SUP>
    Address correspondence to Byron Caughey,

    Editor Reed Wickner, National Institutes of Health


    A key challenge in managing transmissible spongiform encephalopathies (TSEs) or prion diseases in medicine, agriculture, and wildlife biology is the development of practical tests for prions that are at or below infectious levels. Of particular interest are tests capable of detecting prions in blood components such as plasma, but blood typically has extremely low prion concentrations and contains inhibitors of the most sensitive prion tests. One of the latter tests is quaking-induced conversion (QuIC), which can be as sensitive as in vivo bioassays, but much more rapid, higher throughput, and less expensive. Now we have integrated antibody 15B3-based immunoprecipitation with QuIC reactions to increase sensitivity and isolate prions from inhibitors such as those in plasma samples. Coupling of immunoprecipitation and an improved real-time QuIC reaction dramatically enhanced detection of variant Creutzfeldt-Jakob disease (vCJD) brain tissue diluted into human plasma. Dilutions of 10<SUP>14</SUP>-fold, containing ~2 attogram (ag) per ml of proteinase K-resistant prion protein, were readily detected, indicating ~10,000-fold greater sensitivity for vCJD brain than has previously been reported. We also discriminated between plasma and serum samples from scrapie-infected and uninfected hamsters, even in early preclinical stages. This combined assay, which we call “enhanced QuIC” (eQuIC), markedly improves prospects for routine detection of low levels of prions in tissues, fluids, or environmental samples.


    Transmissible spongiform encephalopathies (TSEs) are largely untreatable and are difficult to diagnose definitively prior to irreversible clinical decline or death. The transmissibility of TSEs within and between species highlights the need for practical tests for even the smallest amounts of infectivity. A few sufficiently sensitive in vitro methods have been reported, but most have major limitations that would preclude their use in routine diagnostic or screening applications. Our new assay improves the outlook for such critical applications. We focused initially on blood plasma because a practical blood test for prions would be especially valuable for TSE diagnostics and risk reduction. Variant Creutzfeldt-Jakob disease (vCJD) in particular has been transmitted between humans via blood transfusions. Enhanced real-time quaking-induced conversion (eRTQ) provides by far the most sensitive detection of vCJD to date. The 15B3 antibody binds prions of multiple species, suggesting that our assay may be useful for clinical and fundamental studies of a variety of TSEs of humans and animals.

    • Citation Orrú CD, et al. 2011. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. mBio 2(3):e00078-11. doi:10.1128/mBio.00078-11.
    • Received 8 April 2011
    • Accepted 12 April 2011
    • Published 10 May 2011
    • Copyright © 2011 Orrú et al.
    This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
    - -------